Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pocket-Sized DNA Sequencers Track Malaria Drug Resistance in Near Real-Time

By LabMedica International staff writers
Posted on 05 Dec 2023

Despite ongoing control efforts, malaria continues to be a major global health challenge, claiming over 600,000 lives annually, predominantly among young children in sub-Saharan Africa. More...

A major hurdle in combating malaria has been the parasite’s ability to quickly develop resistance to antimalarial drugs. Genomic surveillance – the continuous monitoring of changes in the parasite’s DNA – enables the analysis of genomic data related to parasite drug resistance. However, until now, this has been performed mostly in distant labs in high-income, non-endemic countries, away from the affected regions. Now, researchers have developed a new method for rapid and reliable detection of genetic mutations in malaria parasites, utilizing just a gaming laptop and a portable sequencer.

This groundbreaking approach developed by researchers from the Wellcome Sanger Institute (Cambridgeshire, UK) and University of Ghana (Accra, Ghana) allows for end-to-end, real-time pathogen monitoring directly in rural, malaria-prone areas with limited resources. The focus of their research was to identify crucial drug resistance markers in the malaria parasite and to examine the diversity within the vaccine target gene. This development is a significant step towards enabling local regions to monitor drug resistance and evaluate the effectiveness of new malaria vaccines.

For their study, the researchers collected parasites from clinical blood samples using standard molecular biology tools and a simple finger prick method. They then sequenced the malaria parasite DNA using the portable MinION sequencer from Oxford Nanopore (Oxford, UK) and a laptop. This allowed them to swiftly identify known drug resistance markers, emerging mutations, and targets of new malaria vaccines, with sequencing information available within just 48 hours after sample collection. The cost of this process was kept low, at approximately GBP 27 per sample for batches of 96.

The study's findings indicated that current frontline treatments are largely effective against the prevalent strains of malaria in Ghana. However, it also highlighted the importance of continuous monitoring, especially to safeguard high-risk groups receiving targeted treatments. The researchers identified several genetic variances between the circulating malaria strains and the protein targeted by new malaria vaccines. Importantly, no evidence of resistance to artemisinins, the best available treatment for P. falciparum malaria, was found. Although mutations related to resistance to sulfadoxine and pyrimethamine (SP) were detected, the more severe mutations leading to high-level resistance to SP were not present. These findings could have implications for the effectiveness of recent vaccine rollouts across Africa and underscore the need for further investigation.

“By taking sequencing to the source, insights arrive in days rather than years — enabling rapid, localized responses,” said Edem Adika, co-first author of the study at University of Ghana. “This unprecedented speed promises to be a powerful game-changer against infectious diseases outpacing our countermeasures. We hope this on-site approach is soon applied here to other pathogens.”

“The repeated evolution and spread of resistance to key antimalarial drugs has thwarted efforts to eliminate malaria over the last 70 years,” added Dr. William Hamilton, senior author of the study at the Wellcome Sanger Institute. “Expanding molecular surveillance in Africa is now critical for tracking emerging drug and diagnostic test resistance, and informing interventions like new vaccines.”

Related Links:
Wellcome Sanger Institute
University of Ghana
Oxford Nanopore 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.